Riskpilot← Back to searchSign inGet full accessAvia Pharma AB
ABActiveOrg 5590128517Birger Jarlsgatan 27Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201520-49 employees
Revenue 2024
SEK 200,5M
-11% vs 2023
EBITDA margin
4.0%
-36% vs 2023
Equity ratio
18.3%
Financial strength
Net profit 2024
SEK -15,8M
-50% vs 2023
| Revenue | SEK 200,5M | -11% |
| EBITDA | SEK 8,1M | -36% |
| Net profit | SEK -15,8M | -50% |
| Total assets | SEK 778,9M | +56% |
| Equity | SEK 142,7M | +83% |
| Employees | — | — |
Legal name
Avia Pharma AB
Org number
5590128517
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
5 maj 2015
Share capital
SEK 300 000
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska varaagent/ombud för läkemedelsbolag i Norden, bedriva utveckling och registrering av egna läkemedel. Bedriva tradingverksamhet gällande främst receptbelagda och receptfria läkemedel genom inköp i Europa, dessa säljs vidare till apotek i Sverige, äga och förvalta aktier och andelar i andra bolag samt därmed förenlig verksamhet.
Address
Birger Jarlsgatan 27
Email
info@aviapharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 125 595 | 152 916 | 195 462 | 198 232 | 217 258 | 224 672 | 200 504 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −1 433 | 10 972 | 768 | 2 190 | 9 636 | 20 557 | 30 996 | 12 605 | 8 056 |
| Depreciation & amort. | −0 | −89 | −275 | −330 | −1 687 | −1 687 | −1 985 | −2 779 | −3 320 |
| EBIT | −1 433 | 10 883 | 493 | 1 860 | 7 949 | 18 870 | 29 011 | 9 826 | 4 736 |
| Net financials | −23 | −122 | −88 | −74 | −1 697 | −1 582 | −26 427 | −20 395 | −32 525 |
| Profit before tax | −1 456 | 8 421 | 405 | 1 277 | 4 654 | 12 935 | 12 062 | −9 013 | −15 848 |
| Tax | −0 | −1 547 | −138 | −330 | −1 027 | −2 690 | −2 547 | −1 519 | −0 |
| Net profit | −1 456 | 6 874 | 267 | 947 | 3 627 | 10 245 | 9 515 | −10 532 | −15 848 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 023 | 37 943 | 36 885 | 86 387 | 94 998 | 104 307 | 503 112 | 497 967 | 778 857 |
| Equity | −456 | 11 418 | 7 685 | 8 632 | 12 259 | 22 503 | 58 394 | 77 861 | 142 707 |
| Long-term debt | 866 | 0 | 0 | 11 200 | 21 891 | 19 938 | 339 235 | 338 510 | 562 606 |
| Short-term debt | 613 | 24 185 | 26 860 | 63 705 | 45 799 | 43 464 | 59 671 | 49 555 | 45 687 |
| Total debt | 1 479 | 24 185 | 26 860 | 74 905 | 67 690 | 63 402 | 398 906 | 388 065 | 608 293 |
EBITDA margin
4.0%
This company
15.8%
Market median
-75% vs market
20162024
Equity ratio
18.3%
This company
38.2%
Market median
-52% vs market
20162024
Return on equity
-11.1%
This company
18.4%
Market median
-160% vs market
20162024
Net profit margin
-7.9%
This company
8.1%
Market median
-198% vs market
20162024
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20162024
Debt / equity
4.46×
This company
0.62×
Market median
-619% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-05-01 – 2016-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
VP Chief Auditor | Chief Auditor | 2021 | — | — |
SL Chief Auditor | Chief Auditor | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Avia Pharma Holding AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Avia Pharma Holding AB
Avia Pharma AB Board members of Avia Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Victor Per Ludwig Lindhall | Chief Auditor | 0 companies |
| Sofia Louise Petersson | Chief Auditor | 0 companies |
| Jonas Bo Karlander | Board of Directors | 0 companies |
| Jacob Christoffer Calmvik | Chairman | 0 companies |
| Olof Tobias Johansson | Deputy Board Member | 0 companies |
| Lars Håkan Wilhelm Jansson | Chairman | 0 companies |